Literature DB >> 24556039

Third-line dovitinib in metastatic renal cell carcinoma.

Manuela Schmidinger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24556039     DOI： 10.1016/S1470-2045(14)70082-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.

Authors:  Mohammad Javed Ansari; Dmitry Bokov; Alexander Markov; Abduladheem Turki Jalil; Mohammed Nader Shalaby; Wanich Suksatan; Supat Chupradit; Hasan S Al-Ghamdi; Navid Shomali; Amir Zamani; Ali Mohammadi; Mehdi Dadashpour
Journal:  Cell Commun Signal       Date:  2022-04-07       Impact factor: 5.712

Review 2.  Sequence of treatment in locally advanced and metastatic renal cell carcinoma.

Authors:  Stefanie Fischer; Silke Gillessen; Christian Rothermundt
Journal:  Transl Androl Urol       Date:  2015-06

Review 3.  Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer.

Authors:  Fatema Tuz Zahra; Md Sanaullah Sajib; Constantinos M Mikelis
Journal:  Cancers (Basel)       Date:  2021-03-20       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.